Table 2. Incident Disease and Death During Follow-up in a Study of the Association of Hemochromatosis HFE p.C282Y Homozygosity With Hepatic Malignancya.
| Characteristics | No. (%) | ||||||
|---|---|---|---|---|---|---|---|
| Males | Females | ||||||
| C282Y +/+ | C282Y+/H63+ | No variants | C282Y +/+ | C282Y+/H63+ | No variants | ||
| Total participantsb | (n = 1294) | (n = 4955) | (n = 122 860) | (n = 1596) | (n = 5746) | (n = 145 719) | |
| Hemochromatosis diagnosis at baseline | 156 (12.1) | 29 (0.6) | 30 (<0.1) | 54 (3.4) | 12 (0.2) | 8 (<0.1) | |
| Hemochromatosis diagnosis at the end of follow-up (baseline or incident) | 327 (25.3) | 89 (1.8) | 74 (0.1) | 200 (12.5) | 35 (0.6) | 25 (<0.1) | |
| Follow-up time, median (IQR), y | 8.9 (8.3-9.5) | 8.9 (8.3-9.5) | 8.9 (8.3-9.5) | 9.0 (8.4-9.5) | 8.9 (8.3-9.5) | 8.9 (8.3-9.5) | |
| Incident diagnoses | |||||||
| Noncancer liver disease | 48 (3.7) | 80 (1.6) | 1598 (1.3) | 23 (1.5) | 68 (1.2) | 1433 (1.0) | |
| Fibrosis and cirrhosis | 17 (1.3) | 16 (0.3) | 264 (0.2) | 4 (0.3) | 9 (0.2) | 229 (0.2) | |
| Alcoholic liver disease | 8 (0.6) | 18 (0.4) | 309 (0.3) | 4 (0.3) | 2 (<0.1) | 77 (0.1) | |
| Chronic hepatitis | 1 (0.1) | 2 (<0.1) | 23 (<0.1) | 1 (0.1) | 1 (<0.1) | 26 (<0.1) | |
| Hepatitis B | 0 | 3 (0.1) | 44 (<0.1) | 1 (0.1) | 1 (<0.1) | 11 (<0.1) | |
| Hepatitis C | 0 | 2 (<0.1) | 53 (<0.1) | 1 (0.1) | 0 | 14 (<0.1) | |
| Liver carcinomas (primary) | 20 (1.6) | 10 (0.2) | 174 (0.1) | 3 (0.2) | 4 (0.1) | 129 (0.1) | |
| Hepatocellular carcinoma | 14 (1.1) | 7 (0.1) | 81 (0.1) | 1 (0.1) | 0 | 30 (<0.1) | |
| Intrahepatic bile duct carcinoma | 5 (0.4) | 3 (0.1) | 63 (0.1) | 0 | 3 (0.1) | 69 (0.1) | |
| Death | |||||||
| All-cause | 88 (6.8) | 260 (5.3) | 6560 (5.3) | 60 (3.8) | 154 (2.7) | 4362 (3.0) | |
| Noncancer liver disease | 1 (0.1) | 5 (0.1) | 141 (0.1) | 0 | 2 (<0.1) | 43 (<0.1) | |
| Liver carcinomas | 14 (1.1) | 6 (0.1) | 102 (0.1) | 3 (0.2) | 3 (0.1) | 78 (0.1) | |
| Participants with primary care recordsc | (n = 612) | (n = 2297) | (n = 56 425) | (n = 770) | (n = 2754) | (n = 67 916) | |
| Incident diagnosis | |||||||
| Noncancer liver disease | 42 (7.1) | 64 (2.8) | 1448 (2.6) | 22 (2.9) | 70 (2.6) | 1305 (1.9) | |
| Fibrosis and cirrhosis | 14 (2.3) | 10 (0.4) | 148 (0.3) | 4 (0.5) | 6 (0.2) | 151 (0.2) | |
| Alcoholic liver disease | 9 (1.5) | 12 (0.5) | 272 (0.5) | 4 (0.5) | 4 (0.2) | 72 (0.1) | |
| Liver carcinomas (primary) | 12 (2.0) | 3 (0.1) | 75 (0.1) | 1 (0.1) | 1 (<0.1) | 62 (0.1) | |
| Hepatocellular carcinoma | 6 (1.0) | 3 (0.1) | 31 (0.1) | 0 | 0 | 16 (<0.1) | |
| Intrahepatic bile duct carcinoma | 4 (0.7) | 0 | 31 (0.1) | 0 | 1 (<0.1) | 31 (0.1) | |
a
Excluding individuals with each prevalent diagnosis at baseline only (eg, the incident liver cancer analysis included participants with baseline noncancer liver disease). p.C282Y heterozygous, p.H63D heterozygous and p.H63D homozygous individuals are not shown (see eTable 3 in the Supplement for details).
b
Total sample (n = 451 186) with follow-up data from Hospital Episode Statistics, the Cancer Registry, and death records.
c
Subset of participants (n = 209 811) with additional follow-up data available from primary care records.